DexCom vs Globus Medical
DXCM and GMED side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DXCM and GMED compare
DexCom is the larger company, worth 3.0 times as much as Globus Medical ($31.1B against $10.5B).
On earnings, Globus Medical is cheaper: it trades at 20.0× trailing earnings, against 32.4× for DexCom.
Globus Medical grew revenue faster over the last twelve months (19.7% versus 13.0% for DexCom).
DexCom keeps more of each dollar of sales as profit, with a net margin of 19.4% compared with 17.0% at Globus Medical.
Globus Medical scores higher on the StockData Score (23 against 22 for DexCom), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DXCM | GMED |
|---|---|---|
| Size and price | ||
| Market cap | $31.1B | $10.5B |
| Share price | $82.29 | $78.05 |
| Change, 1 year | 20.7% | 27.0% |
| Change, 5 years | −48.2% | −0.46% |
| Beta (5Y) | 1.20 | 0.95 |
| Employees | 11K | 6,000 |
| StockData Score | ||
| Total score | 22 | 23 (better) |
| Valuation score | 4 | 6 (better) |
| Growth score | 6 | 6 |
| Performance score | 6 (better) | 5 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 32.4× | 20.0× (better) |
| P/S | 6.1× | 3.3× (better) |
| P/B | 12.2× | 2.2× (better) |
| EV/EBITDA | 20.1× | 10.8× (better) |
| P/FCF | 28.3× | 13.9× (better) |
| PEG | 0.89 | 0.70 (better) |
| FCF yield | 3.5% | 7.2% (better) |
| Fair value | $117.75 | $126.34 |
| Margin of safety | 30.1% | 38.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.0% | 19.7% (better) |
| Revenue growth, 5Y average | 19.3% | 30.1% (better) |
| Net income growth (TTM) | 37.5% | 50.1% (better) |
| EPS growth (TTM) | 41.9% | 50.4% (better) |
| EPS growth, 5Y average | 9.5% | 31.2% (better) |
| Profitability | ||
| Gross margin | 63.4% | 68.5% (better) |
| Operating margin | 24.0% (better) | 20.3% |
| Net margin | 19.4% (better) | 17.0% |
| FCF margin | 21.5% | 24.0% (better) |
| Return on equity | 37.7% (better) | 11.8% |
| Return on invested capital | 78.0% (better) | 12.6% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | 91.3× | – |
| Current ratio | 1.74 | 4.62 (better) |
| Altman Z-score | 7.53 | 10.46 (better) |
| Piotroski F-score | 8 | 9 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.08% | 2.1% (better) |
| Shareholder yield | −0.08% | 2.1% (better) |
| Ownership | ||
| Held by institutions | 102% | 88.9% |
| Held by insiders | 0.52% | 17.8% |
| Insider net buying, 12 months | −$11.6M (better) | −$17.5M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 3.7% | 7.6% |
Go deeper
- DXCM stock overview
- DXCM income statement
- DXCM valuation and score
- GMED stock overview
- GMED income statement
- GMED valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.